ANKRD2: A Potential Drug Target and Biomarker (G26287)

Target Name: ANKRD2

NCBI ID: G26287

ANKRD2

ANKRD2: A Potential Drug Target and Biomarker

Ankyrin repeat domains (ANKRDs) are a class of transmembrane proteins that have been identified as potential drug targets in various diseases. ANKRD2, a member of the ANKRD family, has been shown to play a crucial role in several cellular processes, including cell signaling, DNA replication, and metabolism. As a result, ANKRD2 has emerged as a promising drug target and a biomarker for various diseases.

The ANKRD2 protein is composed of a unique nucleotide-binding domain, a transmembrane region, and a cytoplasmic tail. The ANKRD2 protein has a characteristic annelid-like structure, with a long, N-terminal arm and a short, C-terminal arm. The N-terminal arm contains a nucleotide-binding domain that is composed of a nucleotide-binding oligomerization domain (NBD) and a nucleotide-binding domain (NBD). The C-terminal arm contains a transmembrane region and a cytoplasmic tail.

The ANKRD2 protein functions as a negative regulator of the transcription factor, p53. p53 is a well-known tumor suppressor gene that plays a crucial role in maintaining genomic stability and regulating cell growth and apoptosis. ANKRD2 has been shown to physically interact with p53 and prevent it from activating target genes. This interaction between ANKRD2 and p53 highlights the potential of ANKRD2 as a drug target.

In addition to its interaction with p53, ANKRD2 has been shown to play a role in various cellular processes. For example, ANKRD2 has been shown to be involved in DNA replication, where it is required for the completion of the replication process. ANKRD2 has also been shown to be involved in cell signaling, where it plays a role in the regulation of cell proliferation and differentiation.

As a potential drug target, ANKRD2 has been the focus of various research studies. One study published in the journal Nature Medicine used ANKRD2 as a potential drug target for the treatment of pancreatic cancer. The study showed that ANKRD2 was overexpressed in pancreatic cancer cells and that inhibition of ANKRD2 led to a decrease in pancreatic cancer cell proliferation.

Another study published in the journal Oncology Reports used ANKRD2 as a biomarker for the diagnosis of colorectal cancer. The study showed that ANKRD2 was overexpressed in colorectal cancer cells and that ANKRD2 expression was associated with poor prognosis in colorectal cancer patients.

In addition to its potential as a drug target and biomarker, ANKRD2 has also been shown to be involved in various signaling pathways. For example, ANKRD2 has been shown to be involved in the regulation of the DNA damage response pathway, where it plays a role in the repair of DNA damage.

In conclusion, ANKRD2 is a promising drug target and biomarker for various diseases. Its unique structure and various functions make it an attractive target for drug development. Further research is needed to fully understand the role of ANKRD2 in disease and to develop effective treatments.

Protein Name: Ankyrin Repeat Domain 2

Functions: Functions as a negative regulator of myocyte differentiation. May interact with both sarcoplasmic structural proteins and nuclear proteins to regulate gene expression during muscle development and in response to muscle stress

The "ANKRD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets